Cargando…

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Detalles Bibliográficos
Autores principales:	Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G. N. J., Böhmer, Lara H., van der Poel, Marjolein W. M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E. D., Zijlstra, Josée M., Brink, Mirian, Nijland, Marcel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440142/ https://www.ncbi.nlm.nih.gov/pubmed/36055987 http://dx.doi.org/10.1038/s41408-022-00723-4

Ejemplares similares

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
por: Al-Sarayfi, Diana, et al.
Publicado: (2023)

Successful treatment of hairy cell leukemia variant with obinutuzumab
por: Al-Sarayfi, Diana, et al.
Publicado: (2021)

P1139: COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS
por: Maas, Carolien, et al.
Publicado: (2023)

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
por: Cai, Ming-Ci, et al.
Publicado: (2020)

P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY
por: Pennings, Elise R.A., et al.
Publicado: (2023)

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
por: Geerdes, Emma E., et al.
Publicado: (2023)

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS
por: Meeuwes, F. O., et al.
Publicado: (2022)

Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
por: Durmaz, Müjde, et al.
Publicado: (2022)

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
por: Brink, Mirian, et al.
Publicado: (2022)

P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
por: Spanjaart, A. M., et al.
Publicado: (2022)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
por: de Jonge, V., et al.
Publicado: (2022)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
por: Doorduijn, J., et al.
Publicado: (2022)

Some Aspects of Stammering
por: Boome, E. J.
Publicado: (1934)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
por: Brink, Mirian, et al.
Publicado: (2023)

Indirectly Recognized HLA-C Mismatches and Their Potential Role in Transplant Outcome
por: Thus, Kirsten A., et al.
Publicado: (2014)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Beyond abstraction: applying the brakes to runaway patent ineligibility
por: Burk, Dan L.
Publicado: (2016)

P1170: INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RICHTER’S SYNDROME: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS
por: Huisman, F., et al.
Publicado: (2022)

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
por: Chamuleau, Martine E.D., et al.
Publicado: (2019)

Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Notification Strategy and Predictors of Outcome in Stroke Ineligible for Reperfusion Therapies
por: Mirolovics, Ágnes, et al.
Publicado: (2019)

Office-Based Laryngeal Biopsy in Patients Ineligible for General Anesthesia
por: Mozzanica, Francesco, et al.
Publicado: (2020)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Percutaneous Radiofrequency Ablation of Thyroid Carcinomas Ineligible for Surgery, in the Elderly
por: Marcy, Pierre Yves, et al.
Publicado: (2023)

Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement
por: Hatab, Taha, et al.
Publicado: (2023)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient’s caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial
por: Mendyk, Anne-Marie, et al.
Publicado: (2018)

The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer
por: Brouwer, Thomas P., et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
por: Liu, Jennifer E.
Publicado: (2020)

Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020)

Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_98r7o26peb1a4327j18ujbs3v7